GEORGIA CAPITAL LS 0,01

S&P Global Ratings has raised Georgia Capital's credit rating from BB- to BB and set the outlook to stable. S&P cited balanced fiscal policy, ongoing debt reduction and sustainable shareholder returns as reasons for the decision. The rating matches Georgia's sovereign rating and applies to JSC Georgia Capital's foreign- and local-currency obligations. Georgia Capital holds, among other assets, a 16.6% stake in Lion Finance Group PLC. » More on de.investing.com

Georgia Capital is selling the residential development business m2 to local investors in line with its capital-light strategy. The sale has a slightly positive effect on NAV as of 31 March 2026 and allows the target liquidity buffer to be reduced to USD 25m. Proceeds will be used to repay a USD 25m bond, lifting the pro-forma net cash-to-capital ratio as of 31 March 2026 to 3.1% (up 0.8 percentage points). » More on de.investing.com

Georgia Capital reports aggregated EBITDA of its major private portfolio companies of 73 million GEL for Q1 2026, an increase of 26.9% year-on-year, with revenue up 13.7%. NAV per share remained largely stable in the quarter at 154.82 GEL, but due to a strong share price rise in Lion Finance Group up to 27 April 2026, NAV in GEL has increased 9.2% since the start of the year. The pharmacy business reinforced its market leadership with 244 million GEL in revenue, higher gross margin and an EBITDA margin of 11.9%; the holding shows a strong liquidity position and low net debt. Georgia Capital has so far deployed around 550 million GEL of the ongoing 700 million-GEL capital return program, expects dividend inflows of over 200 million GEL for 2026 and maintains a positive outlook. » More on de.investing.com

Georgia Capital recorded NAV growth of more than 9% year-to-date in Q1 2026 (in GEL +2.1%), with a total portfolio value of around 5 billion GEL. The company repurchased more than one-third of outstanding shares under a buyback program and opened 42 new retail pharmacies; outpatient revenues in the healthcare segment rose 17%. Healthcare services EBITDA was 27 million GEL (+16%), the property and casualty insurance business increased profits by 27%, and management provided 2026 EPS and revenue guidance as well as expected dividend inflows of over 200 million GEL. » More on de.investing.com

Georgia Capital reports a 61.2% increase in net asset value per share in lari for 2025 and a NAV of 154.68 GEL as of 31.12.2025 (further to 162.61 GEL since 30.09.2025). Aggregate EBITDA of large unlisted holdings grew 28.6% in 2025; free cash flow rose to $65m (+52.3% per share). The company completed a $50m share buyback, has returned $246m in capital since 2018 and is using a new return program of 700m GEL through end-2027 (about ~550m GEL deployed by Feb. 2026). Management and analysts highlight strong profitability, balance sheet optimisation (net debt/EBITDA 3.7x) and continued growth plans in the pharmacy, insurance and healthcare segments. » More on de.investing.com